{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:44:31Z","timestamp":1786200271637,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,8]]},"DOI":"10.7759\/cureus.114165","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:26:12Z","timestamp":1786199172000},"source":"Crossref","is-referenced-by-count":0,"title":["Uncovering the Metabolic Origins of Polycystic Ovary Syndrome"],"prefix":"10.7759","author":[{"given":"Pracruti J","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasim","family":"Reza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithisha","family":"Chitteti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajidali S","family":"Saiyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya Emima Raj","family":"Stephen Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navya","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavya","family":"Vats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharssini","family":"Kamaladasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princejeet Singh","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashesh","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2018.04.008","article-title":"Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy","volume":"182","author":"Patel S","year":"2018","unstructured":"Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018, 182:27-36. 10.1016\/j.jsbmb.2018.04.008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede HJ","year":"2026","unstructured":"Teede HJ, Khomami MB, Morman R, et al.. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026, 407:P2329-39. 10.1016\/S0140-6736(26)00717-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurox.2019.100060","article-title":"Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article","volume":"3","author":"Ajmal N","year":"2019","unstructured":"Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article. Eur J Obstet Gynecol Reprod Biol X. 2019, 3:100060. 10.1016\/j.eurox.2019.100060","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2018.04.008","article-title":"Polycystic ovary syndrome","volume":"53","author":"Meier RK","year":"2018","unstructured":"Meier RK. Polycystic ovary syndrome. Nurs Clin North Am. 2018, 53:407-20. 10.1016\/j.cnur.2018.04.008","journal-title":"Nurs Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies","volume":"31","author":"Cassar S","year":"2016","unstructured":"Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016, 31:2619-31. 10.1093\/humrep\/dew243","journal-title":"Hum Reprod"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-18576","article-title":"Insulin resistance: definition and consequences","volume":"109 Suppl 2","author":"Lebovitz HE","year":"2001","unstructured":"Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001, 109 Suppl 2:S135-48. 10.1055\/s-2001-18576","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297718","article-title":"Insulin resistance assessed by short insulin tolerance test and its association with obesity and insulin resistance-related parameters in humans: a pilot randomized trial","volume":"19","author":"Hayashishita A","year":"2024","unstructured":"Hayashishita A, Watanabe T, Suzuki N, et al.. Insulin resistance assessed by short insulin tolerance test and its association with obesity and insulin resistance-related parameters in humans: a pilot randomized trial. PLoS One. 2024, 19:e0297718. 10.1371\/journal.pone.0297718","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.12.015","article-title":"Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism","volume":"115","author":"Ezeh U","year":"2021","unstructured":"Ezeh U, Ezeh C, Pisarska MD, Azziz R. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. Fertil Steril. 2021, 115:1557-68. 10.1016\/j.fertnstert.2020.12.015","journal-title":"Fertil Steril"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0523-8","article-title":"New markers of insulin resistance in polycystic ovary syndrome","volume":"40","author":"Polak K","year":"2017","unstructured":"Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017, 40:1-8. 10.1007\/s40618-016-0523-8","journal-title":"J Endocrinol Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/nu13061848","article-title":"Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility","volume":"13","author":"Calcaterra V","year":"2021","unstructured":"Calcaterra V, Verduci E, Cena H, et al.. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients. 2021, 13:10.3390\/nu13061848","journal-title":"Nutrients"},{"key":"ref11","article-title":"Type 2 diabetes and the polycystic ovary syndrome","volume":"56","author":"Pelusi B","year":"2004","unstructured":"Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004, 56:41-51.","journal-title":"Minerva Ginecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.110759","article-title":"Polycystic ovarian syndrome","volume":"79","author":"Madnani N","year":"2013","unstructured":"Madnani N, Khan K, Chauhan P, Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013, 79:310-21. 10.4103\/0378-6323.110759","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6148","article-title":"A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile","volume":"84","author":"Diamanti-Kandarakis E","year":"1999","unstructured":"Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al.. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999, 84:4006-11. 10.1210\/jcem.84.11.6148","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2015.1009437","article-title":"Mood disorders and quality of life in polycystic ovary syndrome","volume":"31","author":"Podfigurna-Stopa A","year":"2015","unstructured":"Podfigurna-Stopa A, Luisi S, Regini C, Katulski K, Centini G, Meczekalski B, Petraglia F. Mood disorders and quality of life in polycystic ovary syndrome. Gynecol Endocrinol. 2015, 31:431-4. 10.3109\/09513590.2015.1009437","journal-title":"Gynecol Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.08.010","article-title":"Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention","volume":"30","author":"Osibogun O","year":"2020","unstructured":"Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020, 30:399-404. 10.1016\/j.tcm.2019.08.010","journal-title":"Trends Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.202275","article-title":"Cutaneous manifestations of polycystic ovary syndrome: a cross-sectional clinical study","volume":"8","author":"Keen MA","year":"2017","unstructured":"Keen MA, Shah IH, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: a cross-sectional clinical study. Indian Dermatol Online J. 2017, 8:104-10. 10.4103\/2229-5178.202275","journal-title":"Indian Dermatol Online J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000085276","article-title":"Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance","volume":"5","author":"Chari ST","year":"2005","unstructured":"Chari ST, Zapiach M, Yadav D, Rizza RA. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology. 2005, 5:229-33. 10.1159\/000085276","journal-title":"Pancreatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.71","article-title":"Polycystic ovary syndrome as metabolic disease: new insights on insulin resistance","volume":"19","author":"Genazzani AD","year":"2023","unstructured":"Genazzani AD, Genazzani AR. Polycystic ovary syndrome as metabolic disease: new insights on insulin resistance. touchREV Endocrinol. 2023, 19:71-7. 10.17925\/EE.2023.19.1.71","journal-title":"touchREV Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.11.070","article-title":"Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment","volume":"83","author":"DeUgarte CM","year":"2005","unstructured":"DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005, 83:1454-60. 10.1016\/j.fertnstert.2004.11.070","journal-title":"Fertil Steril"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.8.5054","article-title":"A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome","volume":"83","author":"Legro RS","year":"1998","unstructured":"Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998, 83:2694-8. 10.1210\/jcem.83.8.5054","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.11.3265","article-title":"Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals","volume":"54","author":"Dalla Man C","year":"2005","unstructured":"Dalla Man C, Campioni M, Polonsky KS, Basu R, Rizza RA, Toffolo G, Cobelli C. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005, 54:3265-73. 10.2337\/diabetes.54.11.3265","journal-title":"Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.102970","article-title":"Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"18","author":"Belsti Y","year":"2024","unstructured":"Belsti Y, Enticott J, Azumah R, et al.. Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024, 18:102970. 10.1016\/j.dsx.2024.102970","journal-title":"Diabetes Metab Syndr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092230","article-title":"Effect of high fat diet on disease development of polycystic ovary syndrome and lifestyle intervention strategies","volume":"15","author":"Han Y","year":"2023","unstructured":"Han Y, Wu H, Sun S, Zhao R, Deng Y, Zeng S, Chen J. Effect of high fat diet on disease development of polycystic ovary syndrome and lifestyle intervention strategies. Nutrients. 2023, 15:10.3390\/nu15092230","journal-title":"Nutrients"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01091-0","article-title":"Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment","volume":"16","author":"Zhao H","year":"2023","unstructured":"Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023, 16:9. 10.1186\/s13048-022-01091-0","journal-title":"J Ovarian Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038647","article-title":"Polycystic ovary syndrome and its multidimensional impacts on women's mental health: a narrative review","volume":"103","author":"Almhmoud H","year":"2024","unstructured":"Almhmoud H, Alatassi L, Baddoura M, Sandouk J, Alkayali MZ, Najjar H, Zaino B. Polycystic ovary syndrome and its multidimensional impacts on women's mental health: a narrative review. Medicine (Baltimore). 2024, 103:e38647. 10.1097\/MD.0000000000038647","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000519302","article-title":"Dietary interventions: a promising treatment for polycystic ovary syndrome","volume":"77","author":"Che X","year":"2021","unstructured":"Che X, Chen Z, Liu M, Mo Z. Dietary interventions: a promising treatment for polycystic ovary syndrome. Ann Nutr Metab. 2021, 77:313-23. 10.1159\/000519302","journal-title":"Ann Nutr Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger KM","year":"2021","unstructured":"Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021, 106:e1071-83. 10.1210\/clinem\/dgaa839","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102162","article-title":"Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"63","author":"Alesi S","year":"2023","unstructured":"Alesi S, Forslund M, Melin J, et al.. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023, 63:102162. 10.1016\/j.eclinm.2023.102162","journal-title":"EClinicalMedicine"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262987","article-title":"Metformin exposure, maternal PCOS status and fetal venous liver circulation: a randomized, placebo-controlled study","volume":"17","author":"Grindheim S","year":"2022","unstructured":"Grindheim S, Ebbing C, Karlsen HO, et al.. Metformin exposure, maternal PCOS status and fetal venous liver circulation: a randomized, placebo-controlled study. PLoS One. 2022, 17:e0262987. 10.1371\/journal.pone.0262987","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-021-01207-7","article-title":"Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis","volume":"18","author":"Zhao H","year":"2021","unstructured":"Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021, 18:171. 10.1186\/s12978-021-01207-7","journal-title":"Reprod Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad082","article-title":"Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"189","author":"Forslund M","year":"2023","unstructured":"Forslund M, Melin J, Alesi S, et al.. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023, 189:S1-S16. 10.1093\/ejendo\/lvad082","journal-title":"Eur J Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6820377","article-title":"Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations","volume":"2022","author":"Xu D","year":"2022","unstructured":"Xu D, Nair A, Sigston C, et al.. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovasc Ther. 2022, 2022:6820377. 10.1155\/2022\/6820377","journal-title":"Cardiovasc Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185915","article-title":"Do GLP-1 analogs have a place in the treatment of PCOS? new insights and promising therapies","volume":"12","author":"Szczesnowicz A","year":"2023","unstructured":"Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 analogs have a place in the treatment of PCOS? new insights and promising therapies. J Clin Med. 2023, 12:10.3390\/jcm12185915","journal-title":"J Clin Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena H","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020, 105:e2695-709. 10.1210\/clinem\/dgaa285","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmy007","article-title":"Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression","volume":"24","author":"Kakoly NS","year":"2018","unstructured":"Kakoly NS, Khomami MB, Joham AE, et al.. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018, 24:455-67. 10.1093\/humupd\/dmy007","journal-title":"Hum Reprod Update"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185921","article-title":"Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs","volume":"12","author":"Carmina E","year":"2023","unstructured":"Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023, 12:10.3390\/jcm12185921","journal-title":"J Clin Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2017.1294602","article-title":"Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved \u03b2-cell function and insulin sensitivity in metformin treated PCOS","volume":"42","author":"Jensterle M","year":"2017","unstructured":"Jensterle M, Goricar K, Janez A. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved \u03b2-cell function and insulin sensitivity in metformin treated PCOS. Endocr Res. 2017, 42:261-8. 10.1080\/07435800.2017.1294602","journal-title":"Endocr Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2033176","article-title":"Cardioprotection with yet another SGLT2 inhibitor - an embarrassment of riches","volume":"384","author":"Brosius FC","year":"2021","unstructured":"Brosius FC, Vandvik PO. Cardioprotection with yet another SGLT2 inhibitor - an embarrassment of riches. N Engl J Med. 2021, 384:179-81. 10.1056\/NEJMe2033176","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041056","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in the treatment of polycystic ovary syndrome: a review","volume":"13","author":"Porth R","year":"2024","unstructured":"Porth R, Oelerich K, Sivanandy MS. The role of sodium-glucose cotransporter-2 inhibitors in the treatment of polycystic ovary syndrome: a review. J Clin Med. 2024, 13:10.3390\/jcm13041056","journal-title":"J Clin Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.147492","article-title":"Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates","volume":"7","author":"Kumar P","year":"2014","unstructured":"Kumar P, Arora S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci. 2014, 7:255-61. 10.4103\/0974-1208.147492","journal-title":"J Hum Reprod Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.04.003","article-title":"A meta-analysis of bariatric surgery in patients with obesity and polycystic ovary syndrome","volume":"47","author":"Chen M","year":"2024","unstructured":"Chen M, Jia Q, Chen Y, et al.. A meta-analysis of bariatric surgery in patients with obesity and polycystic ovary syndrome. Asian J Surg. 2024, 47:5083-7. 10.1016\/j.asjsur.2024.04.003","journal-title":"Asian J Surg"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-009-0014-5","article-title":"Metabolic\/bariatric surgery worldwide 2008","volume":"19","author":"Buchwald H","year":"2009","unstructured":"Buchwald H, Oien DM. Metabolic\/bariatric surgery worldwide 2008. Obes Surg. 2009, 19:1605-11. 10.1007\/s11695-009-0014-5","journal-title":"Obes Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1871594","article-title":"Bariatric surgery, polycystic ovary syndrome, and infertility","volume":"2016","author":"Butterworth J","year":"2016","unstructured":"Butterworth J, Deguara J, Borg CM. Bariatric surgery, polycystic ovary syndrome, and infertility. J Obes. 2016, 2016:1871594. 10.1155\/2016\/1871594","journal-title":"J Obes"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1641","article-title":"Bariatric surgery: risks and rewards","volume":"93","author":"Pories WJ","year":"2008","unstructured":"Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008, 93:S89-96. 10.1210\/jc.2008-1641","journal-title":"J Clin Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-018-0371-5","article-title":"Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach","volume":"17","author":"Toosy S","year":"2018","unstructured":"Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018, 17:277-85. 10.1007\/s40200-018-0371-5","journal-title":"J Diabetes Metab Disord"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield RL","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016, 37:467-520. 10.1210\/er.2015-1104","journal-title":"Endocr Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1379499","article-title":"Is there a role for kisspeptin in pathogenesis of polycystic ovary syndrome?","volume":"34","author":"Gorkem U","year":"2018","unstructured":"Gorkem U, Togrul C, Arslan E, Sargin Oruc A, Buyukkayaci Duman N. Is there a role for kisspeptin in pathogenesis of polycystic ovary syndrome?. Gynecol Endocrinol. 2018, 34:157-60. 10.1080\/09513590.2017.1379499","journal-title":"Gynecol Endocrinol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmp006","article-title":"Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis","volume":"15","author":"Toulis KA","year":"2009","unstructured":"Toulis KA, Goulis DG, Farmakiotis D, et al.. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009, 15:297-307. 10.1093\/humupd\/dmp006","journal-title":"Hum Reprod Update"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2011.12.010","article-title":"Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?","volume":"31","author":"Muscogiuri G","year":"2012","unstructured":"Muscogiuri G, Policola C, Prioletta A, et al.. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clin Nutr. 2012, 31:476-80. 10.1016\/j.clnu.2011.12.010","journal-title":"Clin Nutr"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.4103\/jhrs.JHRS_78_17","article-title":"Possible link between stress-related factors and altered body composition in women with polycystic ovarian syndrome","volume":"11","author":"Basu BR","year":"2018","unstructured":"Basu BR, Chowdhury O, Saha SK. Possible link between stress-related factors and altered body composition in women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018, 11:10-8. 10.4103\/jhrs.JHRS_78_17","journal-title":"J Hum Reprod Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2013.04.005","article-title":"Changes in the PCOS phenotype with age","volume":"78","author":"Hsu MI","year":"2013","unstructured":"Hsu MI. Changes in the PCOS phenotype with age. Steroids. 2013, 78:761-6. 10.1016\/j.steroids.2013.04.005","journal-title":"Steroids"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01594-5","article-title":"Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome","volume":"44","author":"Falcetta P","year":"2021","unstructured":"Falcetta P, Benelli E, Molinaro A, et al.. Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome. J Endocrinol Invest. 2021, 44:2725-33. 10.1007\/s40618-021-01594-5","journal-title":"J Endocrinol Invest"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz R","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004, 89:2745-9. 10.1210\/jc.2003-032046","journal-title":"J Clin Endocrinol Metab"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz R","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, et al.. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009, 91:456-88. 10.1016\/j.fertnstert.2008.06.035","journal-title":"Fertil Steril"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518508-uncovering-the-metabolic-origins-of-polycystic-ovary-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:26:13Z","timestamp":1786199173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518508-uncovering-the-metabolic-origins-of-polycystic-ovary-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.114165","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,8]]}}}